Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies ...

Brain-meningeal immunity is increasingly recognized as a central player in the complex network of interactions within the central nervous system (CNS).

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

In a recent study published in Nature, researchers developed Sturgeon, a patient-agnostic transfer-learned neural network, to enable molecular subclassification of central nervous system (CNS) ...

Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

- Portfolio available in 60+ markets and deepens our CNS footprint in Brazil, South Africa, France and Italy BASILDON, England--(BUSINESS WIRE)--PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ...

DUBLIN--(BUSINESS WIRE)--The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to ...

The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous System Therapeutics was ...